Neopterin in renal cell carcinoma: inhalational administration of interleukin-2 is not accompanied by a rise of urinary neopterin

Inhalational administration of interleukin‐2 (IL‐2) is effective in controlling renal cell carcinoma (RCC) lung metastases with minimal toxicity. Neopterin is an indicator of systemic immune activation in metastatic cancer and is increased after systemic IL‐2 administration. Urinary neopterin was in...

Full description

Saved in:
Bibliographic Details
Published in:Luminescence (Chichester, England) England), 2005-07, Vol.20 (4-5), p.311-314
Main Authors: Melichar, Bohuslav, Solichová, Dagmar, Svobodová, Iveta, Melicharová, Karolina
Format: Article
Language:English
Subjects:
Administration, Inhalation
Adult
Aged
Aged, 80 and over
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - urine
Female
Humans
interleukin-2
Interleukin-2 - administration & dosage
Interleukin-2 - therapeutic use
Male
Middle Aged
neopterin
Neopterin - urine
renal cell carcinoma
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inhalational administration of interleukin‐2 (IL‐2) is effective in controlling renal cell carcinoma (RCC) lung metastases with minimal toxicity. Neopterin is an indicator of systemic immune activation in metastatic cancer and is increased after systemic IL‐2 administration. Urinary neopterin was investigated in 13 patients with metastatic RCC and 18 controls. In seven patients, urinary neopterin was followed before and after treatment with inhalational IL‐2. Neopterin was measured by highperformance liquid chromatography and creatinine was determined by Jaffé reaction. Urinary neopterin was significantly increased in patients with metastatic RCC compared to controls (257 ± 263 µmol/mol creatinine vs. 110 ± 41 µmol/mol creatinine; Mann–Whitney U‐test, p < 0.05). Median survival was significantly longer in patients with urinary neopterin
ISSN:1522-7235
1522-7243
DOI:10.1002/bio.852